NZ571693A - Pharmaceutical formulations: salts of 8-[{ 1-(3,5-bis-(trifluoromethyl)phenyl)-ethoxy} -methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and treatment methods using the same - Google Patents

Pharmaceutical formulations: salts of 8-[{ 1-(3,5-bis-(trifluoromethyl)phenyl)-ethoxy} -methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and treatment methods using the same

Info

Publication number
NZ571693A
NZ571693A NZ571693A NZ57169307A NZ571693A NZ 571693 A NZ571693 A NZ 571693A NZ 571693 A NZ571693 A NZ 571693A NZ 57169307 A NZ57169307 A NZ 57169307A NZ 571693 A NZ571693 A NZ 571693A
Authority
NZ
New Zealand
Prior art keywords
medicament
phenyl
formulation
salt
hydrochloride monohydrate
Prior art date
Application number
NZ571693A
Other languages
English (en)
Inventor
Zhihui Qiu
Larisa Reyderman
Original Assignee
Opko Health Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38441502&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ571693(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Opko Health Inc filed Critical Opko Health Inc
Publication of NZ571693A publication Critical patent/NZ571693A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14—Nitrogen atoms not forming part of a nitro radical

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NZ571693A 2006-04-05 2007-04-04 Pharmaceutical formulations: salts of 8-[{ 1-(3,5-bis-(trifluoromethyl)phenyl)-ethoxy} -methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and treatment methods using the same NZ571693A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78951406P 2006-04-05 2006-04-05
PCT/US2007/008345 WO2007114921A2 (en) 2006-04-05 2007-04-04 Pharmaceutical formulations: salts of 8-[{1-(3,5-bis (trifluoromethy1)pheny1)-e thoxy}-methy1]-8-pheny1-1,7-diaza-spiro[4.5] decan-2-one and treatment methods using the same

Publications (1)

Publication Number Publication Date
NZ571693A true NZ571693A (en) 2011-12-22

Family

ID=38441502

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ571693A NZ571693A (en) 2006-04-05 2007-04-04 Pharmaceutical formulations: salts of 8-[{ 1-(3,5-bis-(trifluoromethyl)phenyl)-ethoxy} -methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and treatment methods using the same

Country Status (19)

Country Link
US (4) US7563801B2 (enExample)
EP (2) EP2004148B1 (enExample)
JP (4) JP5155998B2 (enExample)
KR (1) KR20080108319A (enExample)
CN (2) CN103751186B (enExample)
AR (1) AR060303A1 (enExample)
AU (1) AU2007233389C1 (enExample)
BR (1) BRPI0710577A2 (enExample)
CA (2) CA2648640C (enExample)
CL (1) CL2007000945A1 (enExample)
ES (1) ES2553805T3 (enExample)
MX (1) MX2008012936A (enExample)
NO (1) NO342810B1 (enExample)
NZ (1) NZ571693A (enExample)
PE (2) PE20080054A1 (enExample)
SG (1) SG10201500028RA (enExample)
TW (1) TWI332836B (enExample)
WO (1) WO2007114921A2 (enExample)
ZA (1) ZA200808465B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20030762A1 (es) 2001-12-18 2003-09-05 Schering Corp Compuestos heterociclicos como antagonistas nk1
CA2648640C (en) * 2006-04-05 2016-02-16 Schering Corporation Pharmaceutical formulations: salts of 8-[{1-(3,5-bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and treatment methods using the same
TWI363058B (en) * 2006-04-05 2012-05-01 Opko Health Inc Hydrochloride salts of 8-[{1-(3,5-bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and preparation process therefor
AR066191A1 (es) * 2007-03-22 2009-08-05 Schering Corp Proceso e intermediarios para la sintesis de compuestos 8- [ ( 1- (3,5- bis- ( trifluorometil) fenil) - etoxi ) - metil]- 8 fenil - 1,7- diaza - espiro (4, 5) decan -2 ona
AR065802A1 (es) * 2007-03-22 2009-07-01 Schering Corp Formulaciones de comprimidos que contienen sales de 8- [( 1- ( 3,5- bis- (trifluorometil) fenil) -etoxi ) - metil) -8- fenil -1, 7- diaza- spiro [ 4,5] decan -2- ona y comprimidos elaborados a partir de estas
CN104496988B (zh) 2008-09-05 2017-04-12 欧科生医股份有限公司 用于合成8‑[{1‑(3,5‑双‑(三氟甲基)苯基)‑乙氧基}‑甲基]‑8‑苯基‑1,7‑二氮杂‑螺[4.5]癸‑2‑酮化合物的方法和中间体
EP2364138A2 (en) * 2008-12-08 2011-09-14 Teva Pharmaceutical Industries Ltd. Palonosetron formulation
EP2464230B1 (en) 2009-08-14 2016-10-05 OPKO Health, Inc. Intravenous formulations of rolapitant
EP3002005A1 (en) 2014-09-30 2016-04-06 Molkerei Meggle Wasserburg GmbH & Co. Kg Direct compression excipient based on lactose, cellulose and starch
CN104473887A (zh) * 2014-11-12 2015-04-01 广东东阳光药业有限公司 一种提高利伐沙班片溶出曲线重现性的方法
CN106866669A (zh) * 2017-04-19 2017-06-20 成都百特万合医药科技有限公司 一种合成罗拉吡坦中间体的方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US431003A (en) * 1890-06-24 Store-service apparatus
GB1605190A (en) * 1968-08-23 1983-03-23 Phillips Petroleum Co Armour plate
US4013613A (en) * 1971-10-01 1977-03-22 General Electric Company Reinforced intercrystalline thermoplastic polyester compositions
US4079161A (en) * 1974-07-12 1978-03-14 Phillips Petroleum Company Transparent oriented polyolefin laminated armor structure
FR2678971B1 (fr) * 1991-07-08 1998-04-10 Andre Giraud Elements de structure composite transparents et leurs procedes de fabrication.
US5830548A (en) * 1992-08-11 1998-11-03 E. Khashoggi Industries, Llc Articles of manufacture and methods for manufacturing laminate structures including inorganically filled sheets
US5665450A (en) * 1992-08-21 1997-09-09 The Curators Of The University Of Missouri Optically transparent composite material and process for preparing same
EP0666856B1 (en) 1992-10-28 2000-01-05 MERCK SHARP & DOHME LTD. 4-arylmethyloxymethyl piperidines as tachykinin antagonists
JPH08504435A (ja) 1992-12-14 1996-05-14 メルク シヤープ エンド ドーム リミテツド タキキニン受容体拮抗剤としての４−アミノメチル／チオメチル／スルホニルメチル−４−フェニルピペリジン
JPH09507500A (ja) 1994-01-13 1997-07-29 メルク シヤープ エンド ドーム リミテツド ｇｅｍ二置換アザシクロ系のタキキニン拮抗薬
US5733659A (en) * 1995-02-27 1998-03-31 Mitsubishi Engineering-Plastics Corporation Transparent rigid resin molded product and process for producing the same
DE69624559T2 (de) * 1995-02-28 2003-07-10 Aventis Pharmaceuticals Inc., Bridgewater Arzneizubereitungen für piperidinalkanolderivate
JPH10511108A (ja) 1995-08-28 1998-10-27 シェーリング コーポレイション テモゾロミドおよびシスプラチンを含む進行ガンに対する組み合わせ治療
US5759658A (en) * 1996-04-26 1998-06-02 Tables International Corporation Composite panels, articles incorporating same and method
US5939098A (en) 1996-09-19 1999-08-17 Schering Corporation Cancer treatment with temozolomide
US6630231B2 (en) * 1999-02-05 2003-10-07 3M Innovative Properties Company Composite articles reinforced with highly oriented microfibers
CN102160864A (zh) * 1999-03-30 2011-08-24 先灵公司 用替莫唑胺改善癌症治疗
US6499984B1 (en) * 2000-05-22 2002-12-31 Warner-Lambert Company Continuous production of pharmaceutical granulation
DE10053151A1 (de) * 2000-10-26 2002-05-08 Bayer Ag Zusammensetzung enthaltend thermoplastische Kunststoffe
EP1451153B1 (en) 2001-11-13 2007-09-26 Schering Corporation Nk1 antagonists
PE20030762A1 (es) 2001-12-18 2003-09-05 Schering Corp Compuestos heterociclicos como antagonistas nk1
US6818306B2 (en) * 2002-09-27 2004-11-16 The Boeing Company Optically clear structural laminate
ES2295924T3 (es) * 2003-10-03 2008-04-16 Pfizer, Inc. Derivados de tropano imidazopirina sustituidos con actividad antagonista de los receptores ccr5 para el tratamiento de vih y de la inflamacion.
US6889938B1 (en) * 2003-10-21 2005-05-10 The Boeing Company Structural cockpit window and method of making same
KR20060113737A (ko) * 2003-12-22 2006-11-02 쉐링 코포레이션 약제학적 조성물
CN101006074B (zh) 2004-07-01 2012-02-15 欧科生医股份有限公司 作为nk1拮抗剂的哌啶衍生物
US20060100188A1 (en) 2004-11-09 2006-05-11 Chen Zong Treatment methods
CA2648640C (en) * 2006-04-05 2016-02-16 Schering Corporation Pharmaceutical formulations: salts of 8-[{1-(3,5-bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and treatment methods using the same
TWI363058B (en) 2006-04-05 2012-05-01 Opko Health Inc Hydrochloride salts of 8-[{1-(3,5-bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and preparation process therefor
AR065802A1 (es) 2007-03-22 2009-07-01 Schering Corp Formulaciones de comprimidos que contienen sales de 8- [( 1- ( 3,5- bis- (trifluorometil) fenil) -etoxi ) - metil) -8- fenil -1, 7- diaza- spiro [ 4,5] decan -2- ona y comprimidos elaborados a partir de estas
AR066191A1 (es) 2007-03-22 2009-08-05 Schering Corp Proceso e intermediarios para la sintesis de compuestos 8- [ ( 1- (3,5- bis- ( trifluorometil) fenil) - etoxi ) - metil]- 8 fenil - 1,7- diaza - espiro (4, 5) decan -2 ona
CN104496988B (zh) 2008-09-05 2017-04-12 欧科生医股份有限公司 用于合成8‑[{1‑(3,5‑双‑(三氟甲基)苯基)‑乙氧基}‑甲基]‑8‑苯基‑1,7‑二氮杂‑螺[4.5]癸‑2‑酮化合物的方法和中间体
EP2464230B1 (en) 2009-08-14 2016-10-05 OPKO Health, Inc. Intravenous formulations of rolapitant

Also Published As

Publication number Publication date
NO20084660L (no) 2008-11-04
NO342810B1 (no) 2018-08-13
KR20080108319A (ko) 2008-12-12
SG10201500028RA (en) 2015-02-27
JP6035305B2 (ja) 2016-11-30
US20140088128A1 (en) 2014-03-27
MX2008012936A (es) 2008-10-15
AR060303A1 (es) 2008-06-04
TWI332836B (en) 2010-11-11
JP5640065B2 (ja) 2014-12-10
ES2553805T3 (es) 2015-12-11
CA2648640C (en) 2016-02-16
CL2007000945A1 (es) 2008-01-25
PE20080054A1 (es) 2008-02-25
JP5415587B2 (ja) 2014-02-12
JP2013049720A (ja) 2013-03-14
PE20120254A1 (es) 2012-03-26
US20070275051A1 (en) 2007-11-29
ZA200808465B (en) 2011-03-30
EP2997964A1 (en) 2016-03-23
JP2009532473A (ja) 2009-09-10
US20120015921A1 (en) 2012-01-19
WO2007114921A3 (en) 2008-03-27
HK1133387A1 (en) 2010-03-26
AU2007233389C1 (en) 2013-07-25
CA2648640A1 (en) 2007-10-11
CN101460151B (zh) 2013-11-20
US20100137348A1 (en) 2010-06-03
EP2004148B1 (en) 2015-07-15
WO2007114921A2 (en) 2007-10-11
EP2004148A2 (en) 2008-12-24
BRPI0710577A2 (pt) 2011-08-16
AU2007233389A1 (en) 2007-10-11
US8404702B2 (en) 2013-03-26
TW200808312A (en) 2008-02-16
US9345692B2 (en) 2016-05-24
AU2007233389B2 (en) 2013-02-28
CA2861281A1 (en) 2007-10-11
US7563801B2 (en) 2009-07-21
CN101460151A (zh) 2009-06-17
JP2012167125A (ja) 2012-09-06
JP5155998B2 (ja) 2013-03-06
JP2015071603A (ja) 2015-04-16
CN103751186B (zh) 2016-08-24
US7981905B2 (en) 2011-07-19
CN103751186A (zh) 2014-04-30

Similar Documents

Publication Publication Date Title
US7981905B2 (en) Pharmaceutical formulations: salts of 8-[{1-(3,5-bis-(trifluoromethyl)phenyl)-Ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and treatment methods using the same
TWI635863B (zh) 帕博西里之固態劑型
HU218673B (hu) Opioid analgetikumot tartalmazó elnyújtott hatóanyag-felszabadítású orális gyógyszerkészítmény és eljárás előállítására
EP2895463A1 (en) Formulations of enzalutamide
SK286865B6 (sk) Multičasticový farmaceutický prostriedok s riadeným uvoľňovaním selektívneho inhibítora spätného príjmu serotonínu a jeho použitie
KR20120130761A (ko) 라미프릴 및 암로디핀 베실레이트의 고형 약제학적 제형, 및 이의 제조
HK1196005A (en) Pharmaceutical formulations: salts of 8-[{1-(3,5-bis-(trifluoromethyl) phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4,5] decan-2-one and treatment methods using the same
HK1133387B (en) Pharmaceutical formulations: salts of 8-[{1-(3,5-bis (trifluoromethyl)phenyl)-ethoxy}- methyl]-8-phenyl-1,7-diaza-spiro[4.5] decan-2-one
TH97790A (th) สูตรผสมเชิงเภสัชกรรม : เกลือของ8-[{1-(3,5-บิส-(ไตรฟลูออโรเมทธิล)ฟีนิล)-เอทธอกซี}-เมทธิล]-8-ฟีนิล-1,7-ไดอะซา-สไปโร[4,5]เดคแคน-2-โอน และวิธีการบำบัดโดยใช้สิ่งดังกล่าว

Legal Events

Date Code Title Description
ASS Change of ownership

Owner name: OPKO HEALTH, INC., US

Free format text: OLD OWNER(S): SCHERING CORPORATION

LCEA Licensees added

Name of requester: TESARO, INC

PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 04 APR 2017 BY COMPUTER PACKAGES INC

Effective date: 20140429

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 04 APR 2018 BY COMPUTER PACKAGES INC

Effective date: 20170318

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 04 APR 2019 BY COMPUTER PACKAGES INC

Effective date: 20180320

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 04 APR 2020 BY COMPUTER PACKAGES INC

Effective date: 20190319

LAPS Patent lapsed